Report of the task force on designing clinical trials in early (predementia) AD

P. S. Aisen, S. Andrieu, C. Sampaio, M. Carrillo, Z. S. Khachaturian, B. Dubois, H. H. Feldman, Ronald Carl Petersen, E. Siemers, R. S. Doody, S. B. Hendrix, M. Grundman, L. S. Schneider, R. J. Schindler, E. Salmon, W. Z. Potter, R. G. Thomas, D. Salmon, M. Donohue, M. M. BednarJ. Touchon, B. Vellas

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Background: A large number of promising candidate disease-modifying treatments for Alzheimer disease (AD) continue to advance into phase II and phase III testing. However, most completed trials have failed to demonstrate efficacy, and there is growing concern that methodologic difficulties may contribute to these clinical trial failures. The optimal time to intervene with such treatments is probably in the years prior to the onset of dementia, before the neuropathology has progressed to the advanced stage corresponding to clinical dementia. Method: An international task force of individuals from academia, industry, nonprofit foundations, and regulatory agencies was convened to discuss optimal trial design in early (predementia) AD. Results: General consensus was reached on key principles involving the scope of the AD diagnosis, the selection of subjects for trials, outcome measures, and analytical methods. Conclusion: A consensus has been achieved in support of the testing of candidate treatments in the early (predementia) AD population.

Original languageEnglish (US)
Pages (from-to)280-286
Number of pages7
JournalNeurology
Volume76
Issue number3
DOIs
StatePublished - Jan 18 2011

Fingerprint

Advisory Committees
Alzheimer Disease
Clinical Trials
Dementia
Consensus
Patient Selection
Industry
Outcome Assessment (Health Care)
Population

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Aisen, P. S., Andrieu, S., Sampaio, C., Carrillo, M., Khachaturian, Z. S., Dubois, B., ... Vellas, B. (2011). Report of the task force on designing clinical trials in early (predementia) AD. Neurology, 76(3), 280-286. https://doi.org/10.1212/WNL.0b013e318207b1b9

Report of the task force on designing clinical trials in early (predementia) AD. / Aisen, P. S.; Andrieu, S.; Sampaio, C.; Carrillo, M.; Khachaturian, Z. S.; Dubois, B.; Feldman, H. H.; Petersen, Ronald Carl; Siemers, E.; Doody, R. S.; Hendrix, S. B.; Grundman, M.; Schneider, L. S.; Schindler, R. J.; Salmon, E.; Potter, W. Z.; Thomas, R. G.; Salmon, D.; Donohue, M.; Bednar, M. M.; Touchon, J.; Vellas, B.

In: Neurology, Vol. 76, No. 3, 18.01.2011, p. 280-286.

Research output: Contribution to journalArticle

Aisen, PS, Andrieu, S, Sampaio, C, Carrillo, M, Khachaturian, ZS, Dubois, B, Feldman, HH, Petersen, RC, Siemers, E, Doody, RS, Hendrix, SB, Grundman, M, Schneider, LS, Schindler, RJ, Salmon, E, Potter, WZ, Thomas, RG, Salmon, D, Donohue, M, Bednar, MM, Touchon, J & Vellas, B 2011, 'Report of the task force on designing clinical trials in early (predementia) AD', Neurology, vol. 76, no. 3, pp. 280-286. https://doi.org/10.1212/WNL.0b013e318207b1b9
Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011 Jan 18;76(3):280-286. https://doi.org/10.1212/WNL.0b013e318207b1b9
Aisen, P. S. ; Andrieu, S. ; Sampaio, C. ; Carrillo, M. ; Khachaturian, Z. S. ; Dubois, B. ; Feldman, H. H. ; Petersen, Ronald Carl ; Siemers, E. ; Doody, R. S. ; Hendrix, S. B. ; Grundman, M. ; Schneider, L. S. ; Schindler, R. J. ; Salmon, E. ; Potter, W. Z. ; Thomas, R. G. ; Salmon, D. ; Donohue, M. ; Bednar, M. M. ; Touchon, J. ; Vellas, B. / Report of the task force on designing clinical trials in early (predementia) AD. In: Neurology. 2011 ; Vol. 76, No. 3. pp. 280-286.
@article{b875e72274744b0e8e389da043e6bfc7,
title = "Report of the task force on designing clinical trials in early (predementia) AD",
abstract = "Background: A large number of promising candidate disease-modifying treatments for Alzheimer disease (AD) continue to advance into phase II and phase III testing. However, most completed trials have failed to demonstrate efficacy, and there is growing concern that methodologic difficulties may contribute to these clinical trial failures. The optimal time to intervene with such treatments is probably in the years prior to the onset of dementia, before the neuropathology has progressed to the advanced stage corresponding to clinical dementia. Method: An international task force of individuals from academia, industry, nonprofit foundations, and regulatory agencies was convened to discuss optimal trial design in early (predementia) AD. Results: General consensus was reached on key principles involving the scope of the AD diagnosis, the selection of subjects for trials, outcome measures, and analytical methods. Conclusion: A consensus has been achieved in support of the testing of candidate treatments in the early (predementia) AD population.",
author = "Aisen, {P. S.} and S. Andrieu and C. Sampaio and M. Carrillo and Khachaturian, {Z. S.} and B. Dubois and Feldman, {H. H.} and Petersen, {Ronald Carl} and E. Siemers and Doody, {R. S.} and Hendrix, {S. B.} and M. Grundman and Schneider, {L. S.} and Schindler, {R. J.} and E. Salmon and Potter, {W. Z.} and Thomas, {R. G.} and D. Salmon and M. Donohue and Bednar, {M. M.} and J. Touchon and B. Vellas",
year = "2011",
month = "1",
day = "18",
doi = "10.1212/WNL.0b013e318207b1b9",
language = "English (US)",
volume = "76",
pages = "280--286",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Report of the task force on designing clinical trials in early (predementia) AD

AU - Aisen, P. S.

AU - Andrieu, S.

AU - Sampaio, C.

AU - Carrillo, M.

AU - Khachaturian, Z. S.

AU - Dubois, B.

AU - Feldman, H. H.

AU - Petersen, Ronald Carl

AU - Siemers, E.

AU - Doody, R. S.

AU - Hendrix, S. B.

AU - Grundman, M.

AU - Schneider, L. S.

AU - Schindler, R. J.

AU - Salmon, E.

AU - Potter, W. Z.

AU - Thomas, R. G.

AU - Salmon, D.

AU - Donohue, M.

AU - Bednar, M. M.

AU - Touchon, J.

AU - Vellas, B.

PY - 2011/1/18

Y1 - 2011/1/18

N2 - Background: A large number of promising candidate disease-modifying treatments for Alzheimer disease (AD) continue to advance into phase II and phase III testing. However, most completed trials have failed to demonstrate efficacy, and there is growing concern that methodologic difficulties may contribute to these clinical trial failures. The optimal time to intervene with such treatments is probably in the years prior to the onset of dementia, before the neuropathology has progressed to the advanced stage corresponding to clinical dementia. Method: An international task force of individuals from academia, industry, nonprofit foundations, and regulatory agencies was convened to discuss optimal trial design in early (predementia) AD. Results: General consensus was reached on key principles involving the scope of the AD diagnosis, the selection of subjects for trials, outcome measures, and analytical methods. Conclusion: A consensus has been achieved in support of the testing of candidate treatments in the early (predementia) AD population.

AB - Background: A large number of promising candidate disease-modifying treatments for Alzheimer disease (AD) continue to advance into phase II and phase III testing. However, most completed trials have failed to demonstrate efficacy, and there is growing concern that methodologic difficulties may contribute to these clinical trial failures. The optimal time to intervene with such treatments is probably in the years prior to the onset of dementia, before the neuropathology has progressed to the advanced stage corresponding to clinical dementia. Method: An international task force of individuals from academia, industry, nonprofit foundations, and regulatory agencies was convened to discuss optimal trial design in early (predementia) AD. Results: General consensus was reached on key principles involving the scope of the AD diagnosis, the selection of subjects for trials, outcome measures, and analytical methods. Conclusion: A consensus has been achieved in support of the testing of candidate treatments in the early (predementia) AD population.

UR - http://www.scopus.com/inward/record.url?scp=78751613397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751613397&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e318207b1b9

DO - 10.1212/WNL.0b013e318207b1b9

M3 - Article

C2 - 21178097

AN - SCOPUS:78751613397

VL - 76

SP - 280

EP - 286

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -